Ravagalimab represents a intriguing development in the treatment of disease. This biologic selectively blocks the function of this specific protein, a protein involved in the recruitment of immune cells. Early clinical trials have shown encouraging outcomes, particularly in inflammatory conditions such as skin disorders. The mechanism of action off